Chronic Spontaneous Urticaria Clinical Trials

153 clinical trials for Chronic Spontaneous Urticaria across international registries, including 39 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT) — RECRUITING
• A Trial of HRS-3095 in Healthy Volunteers — RECRUITING · PHASE1
• A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 (EMBARQ-CSU LTE) — RECRUITING · PHASE3
• Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. — RECRUITING · PHASE3
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria — RECRUITING · PHASE3
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU) — RECRUITING · PHASE1
• A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines — RECRUITING · PHASE3
• A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. — RECRUITING · PHASE2
• Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II study (TAILOR-CSU) — RECRUITING · PHASE2
• A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients — RECRUITING
• Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria — RECRUITING · PHASE2
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults — RECRUITING · PHASE1
• Remibrutinib in Real-world Clinical Practice — RECRUITING
• Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines — RECRUITING · PHASE2
• Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU) — RECRUITING · PHASE2
• Effects of Diet and Oxidative Stress on Disease Severity and Response to Omalizumab in Chronic Spontaneous Urticaria — RECRUITING
• A PHASE 3B LONG-TERM EFFICACY AND SAFETY EXTENSION STUDY OF BARZOLVOLIMAB IN PARTICIPANTS WITH CHRONIC SPONTANEOUS URTICARIA WHO HAVE COMPLETED CDX0159-12 OR CDX0159-13 (EMBARQ-CSULTE) — RECRUITING · PHASE3
• ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar — RECRUITING
• Remibrutinib in Real-world Clinical Practice - a US Sub-study — RECRUITING
• Analysis of the Role of IgE Proteoforms in Health and Disease — RECRUITING
• Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria — RECRUITING · PHASE4
• SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) — RECRUITING
• Trial of JYB1904 in Chronic Spontaneous Urticaria. — RECRUITING · PHASE2
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BARZOLVOLIMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA WHO REMAIN SYMPTOMATIC DESPITE H1 ANTIHISTAMINE TREATMENT (EMBARQ - CSU1) — RECRUITING · PHASE3
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BARZOLVOLIMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA WHO REMAIN SYMPTOMATIC DESPITE H1 ANTIHISTAMINE TREATMENT (EMBARQ - CSU2) — RECRUITING · PHASE3
• AN OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PK, IMMUNOGENICITY, AND CLINICAL RESPONSE OF MULTIPLE DOSES OF IV AK006 IN SUBJECTS WITH H1 ANTIHISTAMINE REFRACTORY CHRONIC SPONTANEOUS URTICARIA COMPLETING STUDY AK006-001 — RECRUITING
• A GLOBAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, PHASE 3B STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF REMIBRUTINIB 25 MG B.I.D. IN COMPARISON TO PLACEBO WITH OMALIZUMAB 300 MG EVERY 4 WEEKS AS ACTIVE CONTROL OVER 52 WEEKS IN ADULT PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED BY SECOND-GENERATION H1-ANTIHISTAMINES, AND AN OPEN-LABEL 52-WEEK OPTIONAL EXTENSION TO ASSESS LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF REMIBRUTINIB 25 — RECRUITING · PHASE3
• A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, PHARMACOKINETICS AND SAFETY OF REMIBRUTINIB (LOU064) FOR 24 WEEKS IN ADOLESCENTS FROM 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED BY H1-ANTIHISTAMINES FOLLOWED BY AN OPTIONAL OPEN-LABEL EXTENSION FOR UP TO ANOTHER 3 YEARS AND AN OPTIONAL SAFETY LONG-TERM TREATMENT-FREE FOLLOW-UP PERIOD FOR UP TO AN ADDITIONAL 3 YEARS — RECRUITING
• A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL AND OPEN-LABEL EXTENSION STUDY FOLLOWED BY LONG-TERM OPEN-LABEL TREATMENT CYCLES TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF REMIBRUTINIB (LOU064) IN ADULT CHRONIC SPONTANEOUS URTICARIA PATIENTS WHO COMPLETED THE PRECEDING REMIBRUTINIB PHASE 3 STUDIES — RECRUITING · PHASE3
• Characterization of biomarkers to identify "responders" and "non-responders" in chronic spontaneous urticaria (CSU) therapy — RECRUITING
• "A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED PILOT AND DOSE-RANGING STUDY OF MTPS9579A IN PARTICIPANTS WITH REFRACTORY CHRONIC SPONTANEOUS URTICARIA — RECRUITING · PHASE2
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING PHASE 2 STUDY OF RILZABRUTINIB FOLLOWED BY AN OPEN-LABEL EXTENSION PHASE IN PATIENTS WITH MODERATE TO- SEVERE CHRONIC SPONTANEOUS URTICARIA (CSU) WHO REMAIN SYMPTOMATIC DESPITE THE USE OF H1 ANTIHISTAMINE TREATMENT, AND WHO ARE NAÏVE TO OMALIZUMAB. — RECRUITING · PHASE2
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSERANGING, PHASE 2B STUDY TO EVALUATE EFFICACY AND SAFETY OF TEZEPELUMAB FOR THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA — RECRUITING · PHASE2
• A MULTI-CENTER, DOUBLE-BLINDED AND OPEN-LABEL EXTENSION STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LIGELIZUMAB AS RETREATMENT, SELF-ADMINISTERED THERAPY AND MONOTHERAPY IN CHRONIC SPONTANEOUS URTICARIA PATIENTS WHO COMPLETED STUDIES CQGE031C2302, CQGE031C2303, CQGE031C2202 OR CQGE031C1301 — RECRUITING
• MASTER PROTOCOL OF TWO RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, PARALLEL-GROUP STUDIES OF DUPILUMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA (CSU) WHO REMAIN SYMPTOMATIC DESPITE THE USE OF H1 ANTIHISTAMINE TREATMENT IN PATIENTS NAIVE TO OMALIZUMAB AND IN PATIENTS WHO ARE INTOLERANT OR INCOMPLETE RESPONDERS TO OMALIZUMAB — RECRUITING
• A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LIGELIZUMAB (QGE031) IN THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA (CSU) IN ADOLESCENTS AND ADULTS INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES — RECRUITING
• AN OPEN LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF QGE031 240 MG S.C. GIVEN EVERY 4 WEEKS FOR 52 WEEKS IN CHRONIC SPONTANEOUS URTICARIA PATIENTS WHO COMPLETED STUDY CQGE031C2201 — RECRUITING
• "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE-CONTROLLED PHASE 2B DOSE-FINDING STUDY OF QGE031 AS ADD-ON THERAPY TO INVESTIGATE THE EFFICACY AND SAFETY IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA (CSU)." — RECRUITING · PHASE2
• OPTIMA: EFFICACY OF OPTIMIZED RE-TREATMENT AND STEP-UP THERAPY WITH OMALIZUMAB IN CHRONIC SPONTANEOUS URTICARIA PATIENTS — RECRUITING
• A long-term safety study for QGE031 as an add-on therapy for adults with CSU who have completed study CQGE031C2201 — COMPLETED · PHASE2
• Study of quality of life in chronic Spontaneous Urticaria patients and treated by omalizumab (Xolair®) — COMPLETED · PHASE4
• Mechanism of action of Xolair (omalizumab) as treatment for hives — ACTIVE_NOT_RECRUITING · PHASE4
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of THB335 in Adult Participants With Chronic Spontaneous Urticaria (CSU) — NOT_YET_RECRUITING · PHASE2
• A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs — NOT_YET_RECRUITING · PHASE2
• Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) — COMPLETED · PHASE1
• Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine — COMPLETED · PHASE2
• A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria — TERMINATED
• Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) — ACTIVE_NOT_RECRUITING · PHASE2
• B7981118 - A Phase 2b Randomized, Double Blind, 12-Week Placebo Controlled Study With a 12-Week Double-Blind Extension Period to Evaluate the Efficacy, Safety and Tolerability of Ritlecitinib (PF 06651600) in Adult Participants with Chronic Spontaneous Urticaria — TERMINATED · PHASE2
• A multicenter, double-blind, placebo-controlled, randomized withdrawal and open-label extension study followed by long-term open-label treatment cycles to assess the efficacy, safety and tolerability of remibrutinib (LOU064) in adult chronic spontaneous urticaria patients who completed the preceding remibrutinib Phase 3 studies) — TERMINATED · PHASE3

Refine this search